Sage Therapeutics Inc (FRA:SG7)
€ 10.175 -0.385 (-3.65%) Market Cap: 589.40 Mil Enterprise Value: -65.07 Mil PE Ratio: 0 PB Ratio: 0.95 GF Score: 49/100

SAGE Therapeutics Inc at Piper Sandler Healthcare Conference Transcript

Dec 01, 2022 / 01:00PM GMT
Release Date Price: €38.59 (+3.02%)
Yas Rahimi
Piper Sandler - Analyst

Good morning, everyone. Welcome to our Piper Healthcare Conference here in New York City. It is day three. My name is Yas Rahimi. I'm a senior biotech analyst here at Piper Sandler. Thrilled to be featuring a great company going after amazing causes, and who've been a pioneer in the space. Sage Therapeutics team, wonderful to have you here from Boston.

We have lots of questions prepared for you. So maybe before we get started, I'm going to let you come and give me a quick overview on where is Sage's key priorities in 2023, as the year is coming to an end.

Unidentified Company Representative

Great. Sure. Thanks, Yas, for having us. And it's great to be back in the city. It's really hustling and bustling out there. So Sage is in the area of brain health. For those of you who aren't familiar with Sage, we've been at it for some time now, made a tremendous amount of progress. So I'll give you the highlights and it's really across three franchise areas. Our depression franchise right now is zuranolone is in the spotlight.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot